VTX 3232
Alternative Names: NLRP3 inflammasome inhibitors - Ventyx Biosciences; VTX-3232Latest Information Update: 23 Jun 2025
At a glance
- Originator Ventyx Biosciences
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Parkinson's disease
- Phase I Neurodegenerative disorders
Most Recent Events
- 17 Jun 2025 Pharmacokinetics, pharmacodynamics and adverse events data from phase IIa clinical trials in Parkinson's disease released by Ventyx Biosciences
- 07 Jan 2025 Phase-II clinical trials in Obesity (Combination therapy) in USA (PO) (NCT06771115)
- 07 Jan 2025 Phase-II clinical trials in Obesity (Monotherapy) in USA (PO) (NCT06771115)